Current protocols and outcomes for colonic cancer

Why do we fail?

K. J. Guleserian, K. I. Bland

Research output: Contribution to journalArticle

Abstract

The 5-year survival rate is more than 90% for people whose colorectal cancer is found and treated in an early stage, before it has spread. Unfortunately, only 37% of colorectal cancers are found at that early stage. As the second leading cause of cancer-related deaths, colorectal cancer remains a significant health problem for American men and women. Advances in diagnosis, screening, surgical techniques, and adjuvant therapy have improved survival over the past 30 years. Multiple clinical trials over the past 20 years have established several standard adjuvant treatment regimens. Although in their infancy, novel approaches to treatment of colorectal cancer offer potential for major advances in the management of colorectal cancer. Continued efforts that focus on disease prevention, along with a better understanding of the tumor biology, cancer immunotherapy, and gene therapy will yield more sophisticated and effective treatment strategies for all patients who either are at risk for or already have been diagnosed with colorectal cancer. As increasing numbers of clinicians, scientists, and health care professionals continue to address these issues, better interventions and therapies are likely to emerge.

Original languageEnglish (US)
Pages (from-to)725-738
Number of pages14
JournalSurgical Oncology Clinics of North America
Volume9
Issue number4
StatePublished - 2000

Fingerprint

Colonic Neoplasms
Colorectal Neoplasms
Therapeutics
Neoplasm Genes
Genetic Therapy
Immunotherapy
Neoplasms
Survival Rate
Clinical Trials
Delivery of Health Care
Survival
Health

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Current protocols and outcomes for colonic cancer : Why do we fail? / Guleserian, K. J.; Bland, K. I.

In: Surgical Oncology Clinics of North America, Vol. 9, No. 4, 2000, p. 725-738.

Research output: Contribution to journalArticle

@article{1459397c52b0466abb9f2b0d4c7a1a41,
title = "Current protocols and outcomes for colonic cancer: Why do we fail?",
abstract = "The 5-year survival rate is more than 90{\%} for people whose colorectal cancer is found and treated in an early stage, before it has spread. Unfortunately, only 37{\%} of colorectal cancers are found at that early stage. As the second leading cause of cancer-related deaths, colorectal cancer remains a significant health problem for American men and women. Advances in diagnosis, screening, surgical techniques, and adjuvant therapy have improved survival over the past 30 years. Multiple clinical trials over the past 20 years have established several standard adjuvant treatment regimens. Although in their infancy, novel approaches to treatment of colorectal cancer offer potential for major advances in the management of colorectal cancer. Continued efforts that focus on disease prevention, along with a better understanding of the tumor biology, cancer immunotherapy, and gene therapy will yield more sophisticated and effective treatment strategies for all patients who either are at risk for or already have been diagnosed with colorectal cancer. As increasing numbers of clinicians, scientists, and health care professionals continue to address these issues, better interventions and therapies are likely to emerge.",
author = "Guleserian, {K. J.} and Bland, {K. I.}",
year = "2000",
language = "English (US)",
volume = "9",
pages = "725--738",
journal = "Surgical Oncology Clinics of North America",
issn = "1055-3207",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Current protocols and outcomes for colonic cancer

T2 - Why do we fail?

AU - Guleserian, K. J.

AU - Bland, K. I.

PY - 2000

Y1 - 2000

N2 - The 5-year survival rate is more than 90% for people whose colorectal cancer is found and treated in an early stage, before it has spread. Unfortunately, only 37% of colorectal cancers are found at that early stage. As the second leading cause of cancer-related deaths, colorectal cancer remains a significant health problem for American men and women. Advances in diagnosis, screening, surgical techniques, and adjuvant therapy have improved survival over the past 30 years. Multiple clinical trials over the past 20 years have established several standard adjuvant treatment regimens. Although in their infancy, novel approaches to treatment of colorectal cancer offer potential for major advances in the management of colorectal cancer. Continued efforts that focus on disease prevention, along with a better understanding of the tumor biology, cancer immunotherapy, and gene therapy will yield more sophisticated and effective treatment strategies for all patients who either are at risk for or already have been diagnosed with colorectal cancer. As increasing numbers of clinicians, scientists, and health care professionals continue to address these issues, better interventions and therapies are likely to emerge.

AB - The 5-year survival rate is more than 90% for people whose colorectal cancer is found and treated in an early stage, before it has spread. Unfortunately, only 37% of colorectal cancers are found at that early stage. As the second leading cause of cancer-related deaths, colorectal cancer remains a significant health problem for American men and women. Advances in diagnosis, screening, surgical techniques, and adjuvant therapy have improved survival over the past 30 years. Multiple clinical trials over the past 20 years have established several standard adjuvant treatment regimens. Although in their infancy, novel approaches to treatment of colorectal cancer offer potential for major advances in the management of colorectal cancer. Continued efforts that focus on disease prevention, along with a better understanding of the tumor biology, cancer immunotherapy, and gene therapy will yield more sophisticated and effective treatment strategies for all patients who either are at risk for or already have been diagnosed with colorectal cancer. As increasing numbers of clinicians, scientists, and health care professionals continue to address these issues, better interventions and therapies are likely to emerge.

UR - http://www.scopus.com/inward/record.url?scp=0033809274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033809274&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 725

EP - 738

JO - Surgical Oncology Clinics of North America

JF - Surgical Oncology Clinics of North America

SN - 1055-3207

IS - 4

ER -